Indeed, Cohen et al. demonstrated that by using bispecific antibody which simultaneously targets LFA-1 and a tumor specific antigen it was possible to specifically block LFA-1-mediated tumor cell adhesion without affecting immune responses in mice (294). The gene discussed is ITGAL; the disease is neoplasm.